What is Immunome's R&D?

Immunome (IMNM) reported R&D of $46.38M in Q1 2026.

How has Immunome's R&D changed year-over-year?

Immunome's R&D increased by 25.8% year-over-year, from $36.87M to $46.38M.

What is the long-term trend for Immunome's R&D?

Over 4 years (2021 to 2025), Immunome's R&D has grown at a 88.3% compound annual growth rate (CAGR), from $14.11M to $177.29M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Immunome IMNM R&D

R&D at other companies

Arcus BiosciencesRCUS

$122M0.0%

Nuvation BioNUVB

$35.05M+42.5%

SELLAS Life Sciences Group, Inc.SLS

$5.13M+60.0%

IDEAYA Biosciences, Inc.IDYA

$95.73M+35.0%

Summit TherapeuticsSMMT

$132.62M+159%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's R&D?: Immunome (IMNM) reported R&D of $46.38M in Q1 2026.
How has Immunome's R&D changed year-over-year?: Immunome's R&D increased by 25.8% year-over-year, from $36.87M to $46.38M.
What is the long-term trend for Immunome's R&D?: Over 4 years (2021 to 2025), Immunome's R&D has grown at a 88.3% compound annual growth rate (CAGR), from $14.11M to $177.29M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.